Literature DB >> 35082565

Low-Titer Group O Whole-Blood Resuscitation in the Prehospital Setting in Israel: Review of the First 2.5 Years' Experience.

Dan Levin1, Maoz Zur2, Eilat Shinar3,4, Tzadok Moshe3,4, Avishai M Tsur1,5, Roy Nadler1,6, Mark H Yazer7,8, Danny Epstein1,9, Guy Avital1,10, Shaul Gelikas1, Elon Glassberg1,11,12, Avi Benov1,11, Jacob Chen1,13.   

Abstract

INTRODUCTION: The Israeli Defense Forces Medical Corps (IDF-MC) implemented the use of low-titer group O whole blood (LTOWB) as the first-choice resuscitation fluid in the IDF airborne Combat Search and Rescue Unit (IDF-CSAR) for aerial evacuation of both military and civilian casualties in June 2018 for injured patients with hemorrhagic shock and at least one of the following: systolic blood pressure <90 mm Hg, heart rate >130 beats/min, deterioration of consciousness without head injury or hemoglobin concentration ≤7 g/dL.
METHOD: All casualties treated with LTOWB by IDF-CSAR providers from June 2018 to January 2021 were included. Demographic and prehospital treatment data were collected in order to check compliance and adherence to the IDF-MC guidelines. This is a follow-up retrospective report.
RESULTS: Overall, 1,608 LTOWB units were supplied to the IDF-CSAR during the study period. Of these, 33 were transfused to 27 casualties; 17 (69%) with blunt injury, 8 (29.6%) with penetrating injuries, and 1 (3.7%) with gastrointestinal bleeding without trauma. The leading cause of injury was motor vehicle accidents. A total of 23 casualties received 1 unit of LTOWB, 3 received 2 units and 1 patient received 4 units. Two casualties were children. The median heart rate was 120 beats/min, 8 (29.6%) casualties had heart rates >130 beats/min. Median systolic blood pressure was 95 mm Hg, 7 (26%) casualties had blood pressure <90 mm Hg. The median Glasgow Coma Score was 14. No adverse reactions were documented following the administration of LTOWB. 77.8% of patients received LTOWB in adherence to the guidelines.
CONCLUSION: Appropriate administration of LTOWB has improved over time in IDF-CSAR. Using LTOWB is feasible and simpler than administering packed red blood cells and plasma concurrently. Further efforts are needed to introduce LTOWB in other prehospital and in-hospital scenarios, with an increase in the maximum antibody titer threshold, to meet the expected increase in demand.
Copyright © 2021 by S. Karger AG, Basel.

Entities:  

Keywords:  Hemorrhagic shock; Low-titer O+ blood; Prehospital setting; Resuscitation; Whole blood

Year:  2021        PMID: 35082565      PMCID: PMC8740175          DOI: 10.1159/000519623

Source DB:  PubMed          Journal:  Transfus Med Hemother        ISSN: 1660-3796            Impact factor:   3.747


  32 in total

1.  Point-of-injury use of reconstituted freeze dried plasma as a resuscitative fluid: a special report for prehospital trauma care.

Authors:  Elon Glassberg; Roy Nadler; Todd E Rasmussen; Amir Abramovich; Tomer Erlich; Lorne H Blackbourne; Yitshak Kreiss
Journal:  J Trauma Acute Care Surg       Date:  2013-08       Impact factor: 3.313

Review 2.  Freeze-dried plasma at the point of injury: from concept to doctrine.

Authors:  Elon Glassberg; Roy Nadler; Sami Gendler; Amir Abramovich; Philip C Spinella; Robert T Gerhardt; John B Holcomb; Yitshak Kreiss
Journal:  Shock       Date:  2013-12       Impact factor: 3.454

3.  Prehospital blood transfusion in prolonged evacuation.

Authors:  Y Barkana; M Stein; R Maor; M Lynn; A Eldad
Journal:  J Trauma       Date:  1999-01

Review 4.  Walking between the drops: Israeli defense forces' fluid resuscitation protocol.

Authors:  Ari M Lipsky; Ori Ganor; Amir Abramovich; Udi Katzenell; Elon Glassberg
Journal:  J Emerg Med       Date:  2012-12-31       Impact factor: 1.484

5.  Operationalizing the Deployment of Low-Titer O-Positive Whole Blood Within a Regional Trauma System.

Authors:  Randall Schaefer; Tasia Long; David Wampler; Rena Summers; Eric Epley; Elizabeth Waltman; Brian Eastridge; Donald Jenkins
Journal:  Mil Med       Date:  2021-01-25       Impact factor: 1.437

6.  Give the trauma patient what they bleed, when and where they need it: establishing a comprehensive regional system of resuscitation based on patient need utilizing cold-stored, low-titer O+ whole blood.

Authors:  Caroline S Zhu; Douglas M Pokorny; Brian J Eastridge; Susannah E Nicholson; Eric Epley; Jason Forcum; Tasia Long; David Miramontes; Randall Schaefer; Michael Shiels; Ronald M Stewart; Michael Stringfellow; Rena Summers; Christopher J Winckler; Donald H Jenkins
Journal:  Transfusion       Date:  2019-04       Impact factor: 3.157

7.  Initial safety and feasibility of cold-stored uncrossmatched whole blood transfusion in civilian trauma patients.

Authors:  Mark H Yazer; Byron Jackson; Jason L Sperry; Louis Alarcon; Darrell J Triulzi; Alan D Murdock
Journal:  J Trauma Acute Care Surg       Date:  2016-07       Impact factor: 3.313

8.  Immediate versus delayed fluid resuscitation for hypotensive patients with penetrating torso injuries.

Authors:  W H Bickell; M J Wall; P E Pepe; R R Martin; V F Ginger; M K Allen; K L Mattox
Journal:  N Engl J Med       Date:  1994-10-27       Impact factor: 91.245

9.  Primary hemostatic capacity of whole blood: a comprehensive analysis of pathogen reduction and refrigeration effects over time.

Authors:  Heather F Pidcoke; Steve J McFaul; Anand K Ramasubramanian; Bijaya K Parida; Alex G Mora; Chriselda G Fedyk; Krystal K Valdez-Delgado; Robbie K Montgomery; Kristin M Reddoch; Armando C Rodriguez; James K Aden; John A Jones; Ron S Bryant; Michael R Scherer; Heather L Reddy; Raymond P Goodrich; Andrew P Cap
Journal:  Transfusion       Date:  2013-01       Impact factor: 3.157

10.  Prehospital Blood Product and Crystalloid Resuscitation in the Severely Injured Patient: A Secondary Analysis of the Prehospital Air Medical Plasma Trial.

Authors:  Francis X Guyette; Jason L Sperry; Andrew B Peitzman; Timothy R Billiar; Brian J Daley; Richard S Miller; Brian G Harbrecht; Jeffrey A Claridge; Tyler Putnam; Therese M Duane; Herb A Phelan; Joshua B Brown
Journal:  Ann Surg       Date:  2021-02-01       Impact factor: 13.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.